A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Public ClinicalTrials.gov record NCT02451943. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Study identification
- NCT ID
- NCT02451943
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 509 participants
Conditions and interventions
Conditions
Interventions
- Doxorubicin Drug
- Olaratumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 13, 2015
- Primary completion
- Dec 4, 2018
- Completion
- Jun 26, 2024
- Last update posted
- Jul 14, 2025
2015 – 2024
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010-0269 | — |
| UCLA Medical Center | Los Angeles | California | 90024 | — |
| Stanford University | Stanford | California | 94305 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | — |
| Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Georgia Cancer Specialists PC | Atlanta | Georgia | 30341 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Washington University Medical School | St Louis | Missouri | 63110 | — |
| Nebraska Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87102 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45202 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45211 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45230 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45236 | — |
| Oncology Hematology Care Inc | Fairfield | Ohio | 45014 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Pennsylvania Oncology Hematology Associates | Philadelphia | Pennsylvania | 19106 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| The West Clinic | Germantown | Tennessee | 38138 | — |
| Oncology Hematology Care Inc | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-6307 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| University of Utah School of Medicine | Salt Lake City | Utah | 84112 | — |
| Fairfax Northern Virginia Hematology Oncology, PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02451943, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02451943 live on ClinicalTrials.gov.